Free Newsletter
SPOTLIGHT: NHS approves drugs
British patients on the National Health Service will get access to two intensive arthritis therapies: MabThera, made by Roche; and Humira, made by Abbott Laboratories. Patient advocacy groups have been lobbying for the drugs since the National Institute for Health and Clinical Excellence (NICE) refused to add Orencia, a similar medication, to the NHS formulary. ReleaseÂ
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: